Department of Neurology, Sydney Children's Hospitals Network, Sydney, NSW 2031, Australia.
Centre for Clinical Genetics, Sydney Children's Hospital, Randwick, Sydney, NSW 2031, Australia.
Genes (Basel). 2023 Jul 6;14(7):1403. doi: 10.3390/genes14071403.
Current carrier screening methods do not identify a proportion of carriers that may have children affected by spinal muscular atrophy (SMA). Additional genetic data is essential to inform accurate risk assessment and genetic counselling of SMA carriers. This study aims to quantify the various genotypes among parents of children with SMA.
A retrospective cohort study was undertaken at Sydney Children's Hospital Network, the major SMA referral centre for New South Wales, Australia. Participants included children with genetically confirmed SMA born between 2005 and 2021. Data was collected on parent genotype inclusive of copy number of exons 7 and 8. The number of exon 7 copies were recorded for the affected children. Descriptive statistics were used to determine the proportion of carriers of 2+0 genotype classified as silent carriers. Chi-square test was used to correlate the association between parents with a heterozygous exon 7 deletion and two copies of exon 8 and ≥3 copy number in the proband.
SMA carrier testing was performed in 118/154 (76.6%) parents, incorporating 59 probands with homozygous deletions and one proband with compound heterozygote pathogenic variants. Among parents with a child with SMA, 7.6% had two copies of exon 7. When only probands with a homozygous exon 7 deletion were included, 6.9% of parents had two copies of exon 7. An association was observed between heterozygous deletion of exon 7 with two copies of exon 8 in a parent and ≥3 copy number in the affected proband ( = 0.07).
This study confirmed a small but substantial proportion of silent carriers not identified by conventional screening within an Australian context. Accordingly, the effectiveness of carrier screening for SMA is linked with genetic counselling to enable health literacy regarding high and low risk results and is complemented by new-born screening and maintaining clinical awareness for SMA. Gene conversion events may underpin the associations between parent carrier status and proband copy number.
目前的携带者筛查方法无法识别出一部分可能生育脊髓性肌萎缩症(SMA)患儿的携带者。额外的遗传数据对于准确评估 SMA 携带者的风险和遗传咨询至关重要。本研究旨在量化 SMA 患儿父母的各种基因型。
这是一项在澳大利亚新南威尔士州主要 SMA 转诊中心悉尼儿童医院网络进行的回顾性队列研究。参与者包括 2005 年至 2021 年间出生的经基因证实患有 SMA 的儿童。收集了包括外显子 7 和 8 拷贝数的父母基因型数据。记录了受影响儿童的外显子 7 拷贝数。采用描述性统计方法确定被归类为沉默携带者的 2+0 基因型携带者的比例。采用卡方检验分析杂合外显子 7 缺失与两个外显子 8 拷贝和患儿≥3 拷贝数之间的关联。
对 154 名(76.6%)父母进行了 SMA 携带者检测,其中包括 59 名纯合缺失和 1 名复合杂合致病性变异的先证者。在有 SMA 患儿的父母中,7.6%有两个外显子 7 拷贝。当仅纳入先证者为纯合外显子 7 缺失时,6.9%的父母有两个外显子 7 拷贝。在外显子 7 杂合缺失与父母中两个外显子 8 拷贝和患儿≥3 拷贝数之间观察到关联( = 0.07)。
本研究在澳大利亚背景下证实了一小部分但数量相当可观的沉默携带者未被常规筛查识别。因此,SMA 携带者筛查的有效性与遗传咨询相关联,以便使携带者了解高风险和低风险结果的健康素养,并通过新生儿筛查和保持对 SMA 的临床认识来补充。基因转换事件可能是父母携带者状态与患儿拷贝数之间关联的基础。